Search Results for: 19

— Oral Presentation to Include Greater Detail on Clinical Outcomes, Including Significant and Unique Improvements in Cognition — ROCKVILLE, Md., July 31, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that Rhonda Voskuhl, […]

ROCKVILLE, Md., July 29, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that in view of the unusual market activity in the Company’s stock, the NYSE MKT (the “Exchange”) has contacted the Company in accordance

Company’s License from The University of Texas at Austin Covers Development of SYN-005 in Collaboration with Intrexon Corporation ROCKVILLE, Md., July 21, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, today announced that Jennifer Maynard, Ph.D.,

— Company Expects to Initiate C. difficile Clinical Trials in 2014 — ROCKVILLE, Md., June 30, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of

— Company’s License Covers C-IBS, Type 2 Diabetes and Obesity — ROCKVILLE, Md., June 25, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, today announced that researchers at Cedars-Sinai Medical Center (Cedars-Sinai) found that eradication of breath

— Study to Define Impact of Beta-Lactam Antibiotics on Intestinal Bacteria — ROCKVILLE, Md. and PARIS, June 10, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and Enterome Bioscience SA, a pioneer in the development of innovative

ROCKVILLE, Md., May 20, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the 3rd Annual Marcum LLP MicroCap Conference on Thursday, May 29, 2014 in New York

— Conference Call Today, May 15, 2014, at 8:30 a.m. (EDT) — ROCKVILLE, Md., May 15, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, today reported financial results for the three months ended March 31, 2014, and

— Conference Call Scheduled for Thursday, May 15, 2014, at 8:30 am EDT — ROCKVILLE, Md., May 9, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it intends to release its financial results

ROCKVILLE, Md., May 8, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it has been granted new patents in Europe and has received a notice of allowance in Australia that provide composition of matter